Paroxysmal Hypertension Associated With Presyncope.
暂无分享,去创建一个
A. Dominiczak | J. Oates | A. Peixoto | R. Carey | G. Jennings | C. Chung | J. M. Luther | F. K. VanDevender
[1] Wei-Qi Wei,et al. Co‐Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine‐Associated Hypotension: A Retrospective Cohort Study , 2018, Clinical pharmacology and therapeutics.
[2] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[3] S. Inomata,et al. Effects of Mexiletine, a CYP1A2 Inhibitor, on Tizanidine Pharmacokinetics and Pharmacodynamics , 2010, Journal of clinical pharmacology.
[4] J. D. Runyan,et al. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients , 2008, International journal of clinical practice.
[5] P. Neuvonen,et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. , 2006, British journal of clinical pharmacology.
[6] P. Neuvonen,et al. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2 , 2005, Clinical pharmacology and therapeutics.
[7] P. Neuvonen,et al. Ciprofloxacin greatly increases concentrations and cypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2–mediated presystemic metabolism , 2004, Clinical pharmacology and therapeutics.
[8] J. Karemaker,et al. Baroreflex failure: a neglected type of secondary hypertension. , 2004, The Netherlands journal of medicine.
[9] P. Neuvonen,et al. Fluvoxamine Drastically Increases Concentrations and Effects of Tizanidine: A Potentially Hazardous Interaction , 2004, Clinical pharmacology and therapeutics.
[10] D. Goldstein,et al. Baroreflex Failure as a Late Sequela of Neck Irradiation , 2003, Hypertension.
[11] I. Biaggioni,et al. Four Faces of Baroreflex Failure: Hypertensive Crisis, Volatile Hypertension, Orthostatic Tachycardia, and Malignant Vagotonia , 2002, Circulation.
[12] O. Kuchel. Peripheral dopamine in hypertension and associated conditions , 1999, Journal of Human Hypertension.
[13] U. Fuhr,et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2 , 1999, Clinical pharmacology and therapeutics.
[14] J. Netterville,et al. The diagnosis and treatment of baroreflex failure. , 1993, The New England journal of medicine.
[15] B. Garrett,et al. Lofexidine in the Treatment of Hypertension: A Twice‐Daily versus Once‐Daily Dose Comparison with 24‐Hour Blood Pressure Monitoring , 1981, Journal of clinical pharmacology.
[16] P. Hamet,et al. Free and Conjugated Dopamine in Pheochromocytoma, Primary Aldosteronism and Essential Hypertension , 1979, Hypertension.
[17] P. Boer,et al. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. , 1979, British journal of clinical pharmacology.
[18] C. Dollery,et al. CLONIDINE WITHDRAWAL IN HYPERTENSION Changes in Blood-pressure and Plasma and Urinary Noradrenaline , 1977, The Lancet.